everolimus / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 471 Diseases   207 Trials   207 Trials   10577 News 


«12...5455565758596061626364...132133»
  • ||||||||||  everolimus / Generic mfg., dasatinib / Generic mfg.
    Clinical, Journal:  Everolimus improves the efficacy of dasatinib in PDGFRα-driven glioma. (Pubmed Central) -  Feb 17, 2021   
    P2
    Although at present there is no role for prophylactic oral anticoagulation after TAVR, once PVT is diagnosed, anticoagulants are the corner stone of treatment. Efficacy of dasatinib treatment of PDGFRα-driven HGG is improved with everolimus and suggests a promising route for improving targeted therapy for this patient population.
  • ||||||||||  cisplatin / Generic mfg.
    Journal:  Inhibition of autophagy improves resistance and enhances sensitivity of gastric cancer cells to cisplatin. (Pubmed Central) -  Feb 9, 2021   
    Then, we discovered that inhibiting autophagy by chloroquine (CQ) significantly enhanced the proliferation-inhibiting and apoptosis-inducing effects of DDP to SGC-7901 and SGC-7901/DDP cells...However, the autophagy inducer everolimus (RAD001) had no obvious effects on the sensitivity of gastric cells to DDP...Additionally, we found interfering Beclin-1using Beclin-1-shRNA also enhanced the proliferation-inhibiting and apoptosis-inducing effects of DDP on gastric cancer cells by inhibiting phosphorylation of Akt. Our study exposures that inhibiting autophagy could improve the chemoresistance and enhanced sensitivity of gastric cancer cells to DDP and provides a rationale that the administration of cisplatin combined with CQ for treating patients with gastric cancer.
  • ||||||||||  prednisone / Generic mfg., everolimus / Generic mfg., sirolimus / Generic mfg.
    Enrollment closed, Trial completion date, Trial primary completion date:  Comparison of the Efficacy and Safety of Sirolimus Versus Everolimus Versus Mycophenolate in Kidney Transplantation (clinicaltrials.gov) -  Feb 9, 2021   
    P4,  N=400, Active, not recruiting, 
    Our present case suggests that early detection and treatment through preemptive HLA antibody screening could improve the prognosis of renal transplants. Recruiting --> Active, not recruiting | Trial completion date: Jun 2021 --> Nov 2021 | Trial primary completion date: Jun 2020 --> Mar 2020
  • ||||||||||  Fumena (vorolanib) / Tyrogenex
    Enrollment closed, Phase classification, Trial completion date, Trial primary completion date, Metastases:  CONCEPT study: CM082 Combined With Everolimus in Chinese Patients With Metastatic Renal Cell Carcinoma (clinicaltrials.gov) -  Feb 8, 2021   
    P3,  N=390, Active, not recruiting, 
    Recruiting --> Active, not recruiting | Trial completion date: Jun 2021 --> Nov 2021 | Trial primary completion date: Jun 2020 --> Mar 2020 Recruiting --> Active, not recruiting | Phase classification: P2/3 --> P3 | Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Nov 2019 --> Feb 2021
  • ||||||||||  everolimus / Generic mfg.
    Trial primary completion date:  RAD001 and Neurocognition in PTEN Hamartoma Tumor Syndrome (clinicaltrials.gov) -  Feb 4, 2021   
    P1/2,  N=40, Active, not recruiting, 
    Active, not recruiting --> Completed Trial primary completion date: Dec 2020 --> Sep 2021